ClinicalTrials.gg
CompletedNCT05800444Updated Aug 21, 2023

A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants

A Phase 1 interventional study of BAY3283142 and Placebo in Chronic Kidney Disease and Healthy Volunteers, sponsored by Bayer. Completed at 1 site in Japan. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Enrollment
26th of 32
24 · median 98
Started
2023
with 4 others
Phase 1
12 of 49
none open now
Registered
34th of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 26th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2023, is one of 12 in phase 1, and was the 34th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 20 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD).

The kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive decrease in the kidneys' ability to work properly.

The study treatment BAY3283142 is under development for treating CKD. It works by activating a protein called soluble guanylate cyclase (sGC) that generates cGMP - a molecule that relaxes blood vessels and is thought to have beneficial effects in CKD.

The participants of this study will be healthy and will have no benefit from the intake of the study treatment. However, the study will provide information on how to use BAY3283142 in subsequent studies in people with CKD.

The main purpose of this study is to learn how safe the study treatment BAY3283142 is and how it affects the body in comparison to placebo when given as single and multiple amounts in healthy male participants in Japan. A placebo is a treatment that looks like a medicine but does not have any medicine in it.

To do this, the study team will compare the number of participants who have medical problems after taking BAY3283142 with those participants who take placebo. These medical problems are called adverse events. The study doctors and their team keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.

Another purpose of this study is to learn how the study treatment BAY3283142 moves into, through, and out of the body. To answer this, the study doctors and their team will take blood samples from the participants and measure:

  • The average highest level of BAY3283142 in the blood (also called Cmax)
  • The average total level of BAY3283142 in the blood (also called AUC).

Dependent on the treatment group, the participants will either take BAY3283142 or placebo as tablet once a day. A group of participants will start out by receiving a low amount of the study treatment. The study doctors will look at the results from these participants and then decide whether to increase the amount of the study treatment in the next group of participants. Researchers use dose escalation studies to learn about the safety of a specific amount before participants are given a higher amount.

Participants will be in the study for up to 7 weeks, including an in-house stay of up to 15 days. One test (screening) visit to the study center is planned before the start of treatment and one follow-up visit is planned after the end of treatment.

During the study, the study team will:

  • check vital signs
  • do physical examinations
  • take blood and urine samples
  • examine the participants' heart health using electrocardiogram (ECG)
03

Conditions studied

  • Chronic Kidney Disease
  • Healthy Volunteers
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 20 to 50 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12 lead .
  • Race: Japanese.
  • (BMI) within the range 18.0 and 29.9 kg/m\^2 (inclusive).
  • Body weight equal or above 55 kg (inclusive).
  • Male: use by men and female partners of male participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Medical disorder, condition, or history of such that would impair the participant's ability to participate or complete this study in the opinion of the investigator.
  • A history of diseases of any organs.
  • Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study interventions will not be normal.
  • Participants with thyroid disorders as evidenced by assessment of thyroid stimulating hormone levels outside the normal reference range.
  • Known to the study interventions (active substances or of the preparations, e.g., lactose).
  • Known severe allergies (e.g., allergies to more than 3 allergens, allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with ), urticaria or significant non-allergic drug reactions.
  • Relevant diseases within the last 4 weeks prior to the first intake of study intervention.
  • Febrile illness within 2 weeks before the first intake of study intervention.
  • Known tendency for vasovagal reactions (e.g., after venipuncture) or history of syncope.
  • History of gastrointestinal surgery, with the exception of appendectomy (surgery at least 12 months before screening) and inguinal hernia repair (the surgery at least 12 months before screening with the documentation of no intestine necrosis and no intestine segment resection, and participants must be fully recovered and have no signs or symptoms).
  • Acute diarrhea or constipation within 14 days before the first intake of study intervention.
  • Regular use of medicines.
  • Use of any other systemic or topical medicines or substances which oppose the study objectives.
  • Regular use of therapeutic or recreational drugs, e.g., carnitine products, anabolics, high dose vitamins.
  • Excluded therapies (e.g., physiotherapy, acupuncture, etc.) within 1 week before the first intake of study intervention.
  • Participation in another clinical study of an drug (last dose) within 90 days or 5 half lives of the investigational drug, whichever is longer, before the first dose of this study.
  • Exclusion periods from other studies or simultaneous participation in other clinical studies.
  • Previous treatment during this study (allowing previously treated participants to be re included into the study may lead to bias).
  • Clinically relevant findings in the 12-lead such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over or equal to 120 msec, or of the or QTcB intervals over 450 msec.
  • Clinically relevant arrhythmic disturbances as found in the 12-lead ECGs (especially repeated supra- and ventricular ectopic beats - Lown classification grade 2 or more); known congenital QT prolongation.
  • Systolic blood pressure (SBP) below 100 or above 140 mmHg (after 15 min of supine rest).
  • Diastolic blood pressure (DBP) below 50 or above 90 mmHg (after 15 min of supine rest).
  • Heart rate (HR) below 45 or above 90 bpm (after 15 min of supine rest).
  • Clinically relevant findings in the physical examination.
  • Positive results for , anti-, antigen and antibody, and syphilis (cardiolipin-lecithin antigen, Treponema pallidum antibody).
  • Creatine kinase (CK) above (ULN), except marginal explainable changes which are expected to normalize before study intervention intake.
  • Lipase and amylase above ULN (except isolated marginal increases of lipase or amylase to account for variability of the parameters, and the participant is asymptomatic and has no other laboratory changes assuming disease based on medical judgment).
  • Glycosylated (), serum creatinine, C-reactive protein (CRP), liver enzymes (e.g., , aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total ) above ULN.
  • Deviations from normal ranges of any other safety laboratory parameter indicating apparent disease (or for which disease cannot be excluded) or impacting the objectives of the study.
  • Positive urine drug screening indicating drug abuse.
  • Positive alcohol breath test.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    BAY3283142 (low dose)

    Participants will receive BAY3283142 as single low dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.

    Drug: BAY3283142

  • Experimental
    BAY3283142 (medium dose)

    Participants will receive BAY3283142 as single medium dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9 (optional arm).

    Drug: BAY3283142

  • Experimental
    BAY3283142 (high dose)

    Participants will receive BAY3283142 as single high dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.

    Drug: BAY3283142

  • Placebo comparator
    Matching placebo

    Participants will receive a BAY3283142 matching placebo as single dose on Day 1 followed by multiple doses for 7 days from Day 3 to Day 9.

    Other: Placebo

Interventions

  • Oral administration as tablet.

  • OtherPlacebo

    Oral administration as tablet.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Up to 7 days after end of treatment with study intervention, an average of 18 days

Secondary outcomes

  1. Area under the concentration versus time curve from zero to infinity (AUC) after single (first) dose of BAY3283142 on Day 1

    Time frame: 0 to 48 hours post-dose

  2. Maximum observed drug concentration (Cmax) after single (first) dose administration of BAY3283142 on Day 1

    Time frame: 0 to 48 hours post-dose

  3. AUC during any dose interval after (last) multiple doses of BAY3283142 on Day 9 (AUCτ,md)

    An interval of 24 h will be used for τ (Tau).

    Time frame: 0 to 24 hours post-dose

  4. Maximum observed drug concentration in measured matrix after (last) multiple doses of BAY3283142 on Day 9 (Cmax,md)

    Time frame: 0 to 24 hours post-dose

07

Study locations

1 site
  • SOUSEIKAI Fukuoka Mirai Hospital
    Fukuoka, 813-0017, Japan
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jul 2023, 3 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2023
First posted
Apr 5, 2023
StartActual
Apr 3, 2023
Primary completionActual
Jul 19, 2023
CompletionActual
Jul 19, 2023
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05800444
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Apr 3, 2023
Primary completion
Jul 19, 2023
Completion
Jul 19, 2023
Last update
Aug 21, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nurandociguat

Start the discussion